Skip to main content
Figure 4 | Breast Cancer Research

Figure 4

From: Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67

Figure 4

Significance of E-cadherin and Ki67 expression in patients with or without adjuvant therapy. (A) In 138 patients who underwent adjuvant therapy, the Kaplan-Meier survival curve showed that a statistically significant difference in the survival was observed in relation to the Ki67 expression and/or E-cadherin expression (P = 0.001). In contrast, no significant difference of prognosis in relation to the Ki67 expression and/or E-cadherin expression was found in 52 cases without adjuvant chemotherapy (P = 0.7768). (B) The prognosis of E-cadherin-negative and Ki67-positive patients was significantly poorer than that of the E-cadherin-positive or Ki67-negative patients at Stage II (P = 0.0316). In contrast, no significant difference of prognosis in relation to the Ki67 expression and/or E-cadherin expression was found in 22 cases without adjuvant chemotherapy at Stage II (P = 0.9427).

Back to article page